DOCSLIB.ORG

RIKEN IMS Annual Report 2019 RIKEN IMS Annual Report 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RIKEN IMS Annual Report 2019 RIKEN IMS Annual Report 2019 RIKEN IMS Annual Report 2019 RIKEN IMS Annual Report 2019 RIKEN Center for Integrative Medical Sciences RIKEN Center for Integrative Medical Sciences RIKEN Center for Integrative Medical Sciences Organization Chart Director Division of Genomic Medicine Tadashi Yamamoto Laboratory for Transcriptome Technology: Piero Carninci Nucleic Acid Diagnostic System Development Unit: Kengo Usui Laboratory for Cellular Function Conversion Technology: Harukazu Suzuki Preventive Medicine and Applied Genomics Unit: Hideya Kawaji Laboratory for Genome Information Analysis: Chung Chau Hon RIKEN-IFOM Joint Laboratory for Cancer Genomics: Yasuhiro Murakawa Deputy Directors Office of the Center Director Laboratory for Applied Computational Genomics: Michel De Hoon Laboratory for Genotyping Development: Yukihide Momozawa Piero Carninci Chikashi Terao Piero Carninci Laboratory for Single Cell Technologies: Laboratory for Statistical and Translational Genetics: Takeya Kasukawa Taisei Mushiroda Haruhiko Koseki Laboratory for Large-Scale Biomedical Data Technology: Laboratory for Pharmacogenomics: Jay W. Shin Taisei Mushiroda Kazuhiko Yamamoto Laboratory for Advanced Genomics Circuit: Laboratory for International Alliance on Genomic Research: Genetic Diagnosis Technology Unit: Kengo Usui Laboratory for Bone and Joint Diseases: Shiro Ikegawa Epigenome Technology Exploration Unit: Aki Minoda Laboratory for Genomics of Diabetes and Metabolism: Momoko Horikoshi Senior Advisor Laboratory for Comprehensive Genomic Analysis: Yasushi Okazaki Laboratory for Cardiovascular Genomics and Informatics: Kaoru Ito Laboratory for Applied Regulatory Genomics Network Analysis: Erik Arner Shizuo Akira Division of Human Immunology Advisory Council Laboratory for Autoimmune Diseases: Kazuhiko Yamamoto Laboratory for Innate Immune Systems: Kazuyo Moro Max Cooper (chair) Laboratory for Human Immunogenetics: Kazuhiko Yamamoto Laboratory for Immune Homeostasis: Taishin Akiyama Mark Lathrop (vice chair) Laboratory for Cell Signaling: Takashi Saito Laboratory for Immune Crosstalk: Hilde Cheroutre Hiroyuki Aburatani Laboratory for Lymphocyte Dierentiation: Tomohiro Kurosaki Laboratory for Inammatory Regulation: Takashi Tanaka Rudi Balling Laboratory for Transcriptional Regulation: Ichiro Taniuchi Laboratory for Cytokine Regulation: Masato Kubo Ewan Birney Laboratory for Immune Cell Systems: Shigeo Koyasu Riccardo Dalla-Favera Michel Georges Ronald N. Germain Division of Disease Systems Biology Yukiko Gotoh David A. Hafler Laboratory for Developmental Genetics: Haruhiko Koseki Laboratory for Tissue Dynamics: Takaharu Okada Yutaka Kawakami Laboratory for Intestinal Ecosystem: Hiroshi Ohno Laboratory for Integrated Cellular Systems: Mariko Okada Juha Kere Laboratory for Integrative Genomics: Osamu Ohara Laboratory for Metabolomics: Makoto Arita Paul W. Kincade Laboratory for Mucosal Immunity: Sidonia Fagarasan Laboratory for Microbiome Sciences: Masahira Hattori Bernard Malissen Laboratory for Gut Homeostasis: Kenya Honda Drug Discovery Antibody Platform Unit: Toshitada Takemori John O'Shea Laboratory for Skin Homeostasis: Masayuki Amagai Fiona Powrie Shimon Sakaguchi Sarah Teichmann Division of Cancer Immunology Arthur Weiss Laboratory for Immunogenetics: Tadashi Yamamoto Laboratory for Immunotherapy: Shin-ichiro Fujii Laboratory for Medical Science Mathematics: Tatsuhiko Tsunoda Laboratory for Human Disease Models: Fumihiko Ishikawa Laboratory for Cancer Genomics: Hidewaki Nakagawa Liver Cancer Prevention Research Unit (Until September): Soichi Kojima RIKEN Hakubi Research Team Genome Immunobiology RIKEN Hakubi Research Team: Nicholas Parrish Young Chief Investigator Program YCI Laboratory for Cellular Bioenergetic: Toshimori Kitami YCI Laboratory for Next-Generation Proteomics: Yibo Wu YCI Laboratory for Trans-omics: Katsuyuki Yugi YCI Laboratory for Metabolic Epigenetics: Azusa Inoue YCI Laboratory for Immunological Transcriptomics: Hideyuki Yoshida Director Division of Genomic Medicine Tadashi Yamamoto Laboratory for Transcriptome Technology: Piero Carninci Nucleic Acid Diagnostic System Development Unit: Kengo Usui Laboratory for Cellular Function Conversion Technology: Harukazu Suzuki Preventive Medicine and Applied Genomics Unit: Hideya Kawaji Laboratory for Genome Information Analysis: Chung Chau Hon RIKEN-IFOM Joint Laboratory for Cancer Genomics: Yasuhiro Murakawa Deputy Directors Office of the Center Director Laboratory for Applied Computational Genomics: Michel De Hoon Laboratory for Genotyping Development: Yukihide Momozawa Piero Carninci Chikashi Terao Piero Carninci Laboratory for Single Cell Technologies: Laboratory for Statistical and Translational Genetics: Takeya Kasukawa Taisei Mushiroda Haruhiko Koseki Laboratory for Large-Scale Biomedical Data Technology: Laboratory for Pharmacogenomics: Jay W. Shin Taisei Mushiroda Kazuhiko Yamamoto Laboratory for Advanced Genomics Circuit: Laboratory for International Alliance on Genomic Research: Genetic Diagnosis Technology Unit: Kengo Usui Laboratory for Bone and Joint Diseases: Shiro Ikegawa Epigenome Technology Exploration Unit: Aki Minoda Laboratory for Genomics of Diabetes and Metabolism: Momoko Horikoshi Senior Advisor Laboratory for Comprehensive Genomic Analysis: Yasushi Okazaki Laboratory for Cardiovascular Genomics and Informatics: Kaoru Ito Laboratory for Applied Regulatory Genomics Network Analysis: Erik Arner Shizuo Akira Division of Human Immunology Advisory Council Laboratory for Autoimmune Diseases: Kazuhiko Yamamoto Laboratory for Innate Immune Systems: Kazuyo Moro Max Cooper (chair) Laboratory for Human Immunogenetics: Kazuhiko Yamamoto Laboratory for Immune Homeostasis: Taishin Akiyama Mark Lathrop (vice chair) Laboratory for Cell Signaling: Takashi Saito Laboratory for Immune Crosstalk: Hilde Cheroutre Hiroyuki Aburatani Laboratory for Lymphocyte Dierentiation: Tomohiro Kurosaki Laboratory for Inammatory Regulation: Takashi Tanaka Rudi Balling Laboratory for Transcriptional Regulation: Ichiro Taniuchi Laboratory for Cytokine Regulation: Masato Kubo Ewan Birney Laboratory for Immune Cell Systems: Shigeo Koyasu Riccardo Dalla-Favera Michel Georges Ronald N. Germain Division of Disease Systems Biology Yukiko Gotoh David A. Hafler Laboratory for Developmental Genetics: Haruhiko Koseki Laboratory for Tissue Dynamics: Takaharu Okada Yutaka Kawakami Laboratory for Intestinal Ecosystem: Hiroshi Ohno Laboratory for Integrated Cellular Systems: Mariko Okada Juha Kere Laboratory for Integrative Genomics: Osamu Ohara Laboratory for Metabolomics: Makoto Arita Paul W. Kincade Laboratory for Mucosal Immunity: Sidonia Fagarasan Laboratory for Microbiome Sciences: Masahira Hattori Bernard Malissen Laboratory for Gut Homeostasis: Kenya Honda Drug Discovery Antibody Platform Unit: Toshitada Takemori John O'Shea Laboratory for Skin Homeostasis: Masayuki Amagai Fiona Powrie Shimon Sakaguchi Sarah Teichmann Division of Cancer Immunology Arthur Weiss Laboratory for Immunogenetics: Tadashi Yamamoto Laboratory for Immunotherapy: Shin-ichiro Fujii Laboratory for Medical Science Mathematics: Tatsuhiko Tsunoda Laboratory for Human Disease Models: Fumihiko Ishikawa Laboratory for Cancer Genomics: Hidewaki Nakagawa Liver Cancer Prevention Research Unit (Until September): Soichi Kojima RIKEN Hakubi Research Team Genome Immunobiology RIKEN Hakubi Research Team: Nicholas Parrish Young Chief Investigator Program YCI Laboratory for Cellular Bioenergetic: Toshimori Kitami YCI Laboratory for Next-Generation Proteomics: Yibo Wu YCI Laboratory for Trans-omics: Katsuyuki Yugi YCI Laboratory for Metabolic Epigenetics: Azusa Inoue YCI Laboratory for Immunological Transcriptomics: Hideyuki Yoshida I Contents Organization ...............................................................................I Director’s Report .....................................................................IV Contents ......................................................................................II Part 1 Research Highlights Rare human gut bacterial strains exhibit potential as Genome-wide genetic analysis of type 2 diabetes in the broadly effective biotherapeutics ...................................... 2 Japanese population ............................................................ 5 Systematic analysis of immune cells toward future Genomic and transcriptomic profiling of combined immunology ......................................................................... 3 hepatocellular and intrahepatic cholangiocarcinoma New method provides better understanding of how gene reveals distinct molecular subtypes .................................. 6 “enhancers” work ................................................................. 4 Part 2 Lab Activities Division of Genomic Medicine ........................................ 8 Laboratory for Lymphocyte Differentiation .................. 30 Laboratory for Transcriptome Technology ...................... 9 Laboratory for Transcriptional Regulation .................... 31 Laboratory for Cellular Function Conversion Laboratory for Immune Cell Systems ............................. 32 Technology ................................................................... 10 Laboratory for Innate Immune Systems ........................ 33 Laboratory for Genome Information Analysis ............. 11 Laboratory for Immune Homeostasis ............................ 34 Laboratory for Applied Computational Genomics....... 12 Laboratory for Immune Crosstalk .................................. 35 Laboratory for Large-Scale Biomedical Data
Load more

Recommended publications
  • 2008 Keio Medical Science Prize Winner Announcement
    FOR IMMEDIATE RELEASE http://www.keio.ac.jp/ October 2, 2008 2008 Keio Medical Science Prize Winner Announcement Keio University presents the “Keio Medical Science Prize” to researchers in recognition of their outstanding achievements in the fields of medical or life sciences. It is the only prize of its kind to be awarded by a Japanese university. The 13th Keio Medical Science Prize will be awarded to Dr. Fred H. Gage and Dr. Shimon Sakaguchi. Fred H. Gage, Ph.D. Adler Professor, Laboratory of Genetics, The Salk Institute for Biological Studies, U.S.A. For the discovery of physiological roles of adult neurogenesis in mammalian brain Shimon Sakaguchi, M.D., Ph.D. Professor, Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Japan For the discovery of regulatory T cells and their roles in immunological diseases Award Ceremony and Commemorative Symposium The award ceremony and a commemorative lecture given by the prize winners will be held on November 21, 2008 and a commemorative symposium will take place on November 22. Both events will be held at the Keio University School of Medicine (Shinanomachi Campus). Please contact below for any inquiries. (eg. interviews or photographs) Attachments : (1) About the Keio University Medical Science Fund (2)2008 Prize Winner: Fred H. Gage（Theme, CV, message） (3)2008 Prize Winner: Shimon Sakaguchi（Theme, CV, message） (4)2008 Keio Medical Science Prize Award Ceremony/Commemorative Lecture/ Commemorative Symposium Inquiries: Keio University Medical Science Fund（Ms. Masako Kawai, Ms. Akiko Murai） TEL: +81-3-5363-3609 URL: http://www.ms-fund.keio.ac.jp/prize/ FAX: +81-3-5363-3610 E-mail:[email protected] 1/5 Attachment About the Keio University Medical Science Fund Background In 1994, Dr.
    [Show full text]
  • Curriculum Vitae
    Curriculum Vitae Name in Full: Shimon Sakaguchi Birth Date: January 19, 1951 Institutions Attended: Kyoto University Premedical Course 1970-1972 Kyoto University Medical School 1972-1976 Degrees Acquired: Doctor of Medicine (M.D.) 1976 Doctor of Philosophy (Ph.D.) 1983 Research and Professional Experiences: Resident, Department of Pathology, Kyoto University Medical School and Hospital 1976-1978 Visiting Investigator, Laboratory of Pathology Aichi Cancer Center Research Institute 1978-1981 Senior Research Fellow, Institute for Immunology Kyoto University Medical School 1981-1983 Joint Appointment at the Blood Transfusion Service, Kyoto University Hospital 1981-1983 Postdoctoral Fellow, Department of Immunology and Infectious Diseases, The Johns Hopkins Medical Institutions 1983-1985 Postdoctoral Fellow (Lucille P. Markey Scholar), Department of Biophysics The Johns Hopkins Medical Institutions 1986-1987 Visiting Scientist, Division of Immunology and Rheumatology, Stanford University Medical Center 1987-1989 Assistant Professor, Department of Immunology, Scripps Research Institute 1989-1991 Investigator, Science and Technology Agency of Japan 1992-1994 Head, Department of Immunopathology, Tokyo Metropolitan Institute of Gerontology 1994-1997 Chair and Professor, Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University 1998-2011 Director, Institute for Frontier Medical Sciences, Kyoto University 2007-2011 Visiting Professor, Institute for Frontier Medical Sciences, Kyoto University 2011-present Professor, Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University 2011-present Adjunct Professor of Oncology, Roswell Park Cancer Institute, USA 2012-present Vice-director, Immunology Frontier Research Center, Osaka University 2012 –present Distinguished Professor, Osaka University 2013-present President of Japanese Society of Immunologists 2016-present Awards and honors: Lucille P. Markey Scholar Award in Biomedical Science 1986 Mochida Science Award 2003 Cancer Research Institute’s William B.
    [Show full text]
  • September 29 (Saturday)
    INFORMATION DAY 1 AM LS PM Posters DAY 2 AM LS PM Posters DAY 3 AM LS PM Posters INDEX Authors Keywords Chairpersons 3 2 2 ) n o y i t a a i d c r 3 o s u s t A a r S e y ( c n 9 a a 2 C r e s e e b n D a p m a J e t e p h t e f S o g n i t e e M l a u n n A h t 7 7 e h T Room 2 Sep. 29 (Sat.) 8:00-8:50 J Room 6 Sep. 29 (Sat.) 8:00-8:50 J Morning Lectures 14 Morning Lectures 18 ML14 ML18 Chairperson: Satoru Miyano (IMS, the Univ. of Tokyo) Chairperson: Kenkichi Masutomi (Natl. Cancer Ctr.) 座長：宮野 悟（東京大・医科研） 座長：増富 健吉（国立 がん 研究 セ・ 研／ がん 幹細胞研究分野） ML14 Integrated analysis of myeloid neoplasms ML18 Long non-coding RNA and cancer Seishi Ogawa (Dept. Pathology and Tumor Biology, Kyoto Univ.) Tetsu Akiyama (Lab. Genet. Mol. Info., Inst. Quan. Bios., Univ. 骨髄系腫瘍 の統合的分子解析 Tokyo) 小川 誠司（京都大・院医・腫瘍生物学） Long non-coding RNA とがん 秋山 徹（東京大・定量研・分子情報） MDL1i4s-cDiuscsussaant t Discussant Hirotoshi Akita (Dept. Med. Oncol., Faculty Med., Hokkaido Univ.) Naohiro Nishida (Dept. Gastrointestinal Surg., Osaka Univ.) 秋田 弘俊（北海道大・院医・腫瘍内科） 西田 尚弘（大阪大・院医学研究科 消化器外科学） Room 3 Sep. 29 (Sat.) 8:00-8:50 J Room 7 Sep. 29 (Sat.) 8:00-8:50 J Morning Lectures 15 Morning Lectures 19 ML15 ML19 Chairperson: Toshirou Nishida (Natl.
    [Show full text]
  • Submit Your Late Breaking Abstract!
    Volume 7 Issue 1 April 2015 NEWSLETTERA Quarterly Publication of the Society for Mucosal Immunology Lori Rathje Named Pillars In ICMI 2015 SMI at Featured SMI Executive Director Immunology Speakers Immunology 2015 Papers Submit your Late Breaking Abstract! Still want to present your science in Berlin? Submit your abstract to the only meeting that focuses exclusively on the mucosal immune system. Late breaking abstract submission closes on Wednesday, April 15th. Submit today! To submit your abstract, click here. July 14th - 18th • Berlin, Germany Lori Rathje, CAE Mucosal Immunology School: Named Executive Pillars in Immunology Director of SMI Mucosal Immunology School Chairs Ifor Williams, Chiara Romagnani, MD, PhD MD, PhD Emory Univeristy German Rheumatism Research Center Berlin Lori Rathje, CAE, has been named Executive SMI has programmed a one day Mucosal Immunology School: Pillars in Immunology, Director of the Society for which will take place on Tuesday, July 14, before ICMI 2015. The overall aim of this Mucosal Immunology. Lori program is to facilitate a deeper understanding of the fundamentals of the immune was previously Association Manager for SMI system at mucosal surfaces. It will provide a broad overview of several core mucosal and served in that position since 2008. immunology topics and has been designed for graduate students and post-docs who have recently entered the field, as well as more experience researchers who are “I am honored to serve as Execu- interested in a concise refresher course. tive Director of SMI, and to have The faculty of this special educational event is the opportunity to work with such comprised of outstanding international experts who have made seminal contributions to the field.
    [Show full text]
  • In This Issue…
    AAI Councillors Visit Capitol Hill, Extol Value of NIH Research See page 3 N FASEB Celebrates Its Centennial 12 AAI Looks Back—The 1918–1919 In This Issue… on Capitol Hill Influenza Pandemic 2 2012 AAI Election Results N NCATS Forms Industry Partnership 14 2012 AAI Annual Meeting Highlights N Does Your Degree Impact Your ™ 3 Focus on Public Affairs: 22 IMMUNOLOGY 2012 Sponsors NIH Funding Prospects? N AAI Holds Special Session on 24 Grant & Award Deadlines N New Dual Use Research Policy NIH Peer Review 28 Meetings Calendar N NIH Director Collins on TV N AAI Research Advocacy Program Engages 5 Key Partners 7 2012 AAI Advanced Immunology Cover Image: Course Program N FY 2013 NIH Funding Bill Clears Galacidalacidesoxiribunucleicacid Senate Committee 8 Members in the News See page 3 for details. 2012 AAI Election Results AAI congratulates the following members on their election to offices and committees for terms commencing July 1, 2012, and extends a sincere thanks to all candidates for their willingness to run and serve if elected. President (2012–2013) Nominating Committee The American Association Gail A. Bishop, Ph.D. (2012–2013) of Immunologists Carver College of Medicine Pamela S. Ohashi, Ph.D., F.R.S.C., Chair 9650 Rockville Pike Distinguished Professor of Microbiology Senior Scientist and Director Bethesda, MD 20814-3994 and Internal Medicine and Holden Immune Therapy Program Tel: 301-634-7178 Chair of Cancer Biology Ontario Cancer Institute Fax: 301-634-7887 University of Iowa Michael Croft, Ph.D. E-mail: [email protected] www.aai.org Vice-President (2012–2013) Professor and Head, Division of Marc K.
    [Show full text]
  • 1 International Symposium on Carcinogenic Spiral & 9
    1st International Symposium on Carcinogenic Spiral & 9th International Conference on Protein Phosphatase February 1 (Tue) – 3 (Thu), 2011 Tetsumon Memorial Hall, The University of Tokyo, Japan Organizer Masanori HATAKEYAMA, M.D. Ph.D. 1 Welcoming Address Welcome to the Joint Meeting of the 1st International Symposium on Carcinogenic Spiral and the 9th International Conference on Protein Phosphatase. As the organizer, I am delighted to host many eminent scholars from Japan as well as overseas. During the Conference, you will be able to learn about exciting up-to-date discoveries in the field of protein phosphatase research. I also would like to emphasize that the second day of the conference will provide a unique scientific opportunity that admixes cutting-edge research on tyrosine phosphatases with cutting-edge research on infection, inflammation and cancer. This special session was made possible by the generous support from Scientific Research on Innovative Areas, a MEXT Grant-in Aid Project. I hope that all of the participants will benefit from valuable scientific information and fruitful discussions throughout the 3-day Conference. I would like to again express a warm-hearted welcome to all of you gathered here. I also express my special thanks to those who have taken time out of their busy schedule to be here. I hope that all of the participants enjoy the Conference and also enjoy Tokyo, a city with lots of fun and excitement. Best regards, Masanori Hatakeyama, M.D., Ph.D. Organizer 1st International Symposium on Carcinogenic Spiral 9th International Conference on Protein Phosphatase 2 General Information Congress 1st International Symposium on Carcinogenic Spiral & 9th International Conference on Protein Phosphatase Date February 1 (Tue) – 3 (Thu), 2011 Venue Tetsumon Memorial Hall Hongo Campus, The University of Tokyo 14th floor of Faculty of Medicine Experimental Research Bldg.
    [Show full text]
  • World Premier International Research Center Initiative (WPI) FY2014 WPI Project Progress Report (Post-Interim Evaluation)
    World Premier International Research Center Initiative (WPI) FY2014 WPI Project Progress Report (Post-Interim Evaluation) Host Institutio n Osaka University Host Institution Head Toshio Hirano Research Cente r Immunology Frontier Research Canter Center D ire ctor Shizuo Akira Common instructions: * Unless otherwise specified, prepare this report from the timeline of 31 March 2015. * So as to base this fiscal year’s follow-up review on the document ”Post-interim evaluation revised center project,” please prepare this report from the perspective of the revised project. * Use yen (¥) when writing monetary amounts in the report. If an exchange rate is used to calculate the yen amount, give the rate. Summary of State of WPI Center Project Progress (write within two pages) IFReC was established as a leading Institute in Immunology and Medicine in Osaka University through the support of WPI program. Our institute provides a highly equipped research platform for young next generation researchers and world premier scientists who have contributed greatly in studies of cytokines, molecular mechanisms of innate immunity, cell death, and regulation of immune system. Our mission in WPI is to accelerate immunology research as well as develop fusion studies with other fields, systems reform of the host institute, and globalization of university and our society. Research of the highest world level: IFReC has continued to publish high quality research activities in highly reputable academic journals during FY2014 in innate immunity, acquired immunity, and the immune regulatory mechanism under the prominent leadership of center director Shizuo Akira, with 195 “WPI papers”, whose author(s) can be identified as affiliated with the WPI program.
    [Show full text]
  • Nod2-Independent Mechanism Bacteria Is Mediated by a TLR- And
    IFN Regulatory Factor 3-Dependent Induction of Type I IFNs by Intracellular Bacteria Is Mediated by a TLR- and Nod2-Independent Mechanism This information is current as of September 27, 2021. Silvia Stockinger, Benjamin Reutterer, Barbara Schaljo, Carola Schellack, Sylvia Brunner, Tilo Materna, Masahiro Yamamoto, Shizuo Akira, Tadatsugu Taniguchi, Peter J. Murray, Mathias Müller and Thomas Decker J Immunol 2004; 173:7416-7425; ; Downloaded from doi: 10.4049/jimmunol.173.12.7416 http://www.jimmunol.org/content/173/12/7416 http://www.jimmunol.org/ References This article cites 75 articles, 41 of which you can access for free at: http://www.jimmunol.org/content/173/12/7416.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IFN Regulatory Factor 3-Dependent Induction of Type I IFNs by Intracellular Bacteria Is Mediated by a TLR- and Nod2-Independent Mechanism1 Silvia Stockinger,2* Benjamin Reutterer,2* Barbara Schaljo,* Carola Schellack,† Sylvia Brunner,† Tilo Materna,* Masahiro Yamamoto,§ Shizuo Akira,§ Tadatsugu Taniguchi,¶ Peter J.
    [Show full text]
  • Osaka University Freedom and Enthusiasm
    Osaka University Freedom and enthusiasm . Where people grow and dream. Tekijuku(適塾) Koan Ogata(緒方洪庵) A pioneer in Japanese modern medical science Medicine Science Engineering Yuichi Shiro Engineering Nobuaki Yamamura IMCB Akabori Science KiKumagai Innovation by fusion World leading immunologists A pioneer in imaging Kishimoto Akira Yanagida Order of culture NAS member The imperial prize The imppperial prize Immunology Frontier Research Center World Premier Initiative (WPI) Program Why is a spatiotemporal approach important in immunology? Innate response Adaptive response Dynamic immune cellular networks Characteristics of immune system T cell differentiation • Largg(e number (1011))y and variety of cells • Migration whole through the body • Dynamic cellular interaction A variety of immune cells move around and form a dynamic network in the body Individual cells are influenced byyg interacting with other cells in the network The balance of immune resppyonses in the body cannot be deduced from isolated cell studies Imaging of spatiotemporal immune reactions in the body Development of imaging techniques Single molecule imaging Multiphoton microscopy MRI (11.7T) ligand GPCR PIP2 Lymph node PTEN Lyypmph node PIP3 Intracellular signaling Cell movement and interaction Immune cell localization From immuno-imaging to translational research Imaging of the immune system Evaluation of cancer immunotherapy Patterning of immune cell dynamics Imaging of lymph node Therapy Cancer- Normal Cancer Allergy attacking T cell Autoimmune disease Cancer Successful
    [Show full text]
  • World Premier International Research Center Initiative (WPI) Executive Summary (For Final Evaluation)
    World Premier International Research Center Initiative (WPI) Executive Summary (for Final Evaluation) Host Institution Osaka University Host Institution Head Shojiro Nishio Research Center Immunology Frontier Research Center Center Director Shizuo Akira About filling out this form: This summary is to be based on the Center’s Progress Report and Progress Plan, with reference to the following items, prepare the summary within a space of up to 6 pages. A. Progress Report of the WPI Center I. Summary IFReC was started as a sustainable innovative World Premier Institute of immunology in Osaka University. Our mission as a WPI is to accelerate immunology research as well as develop interdisciplinary studies with other fields, globalization of the university and our society, and system reform of the host institute. Headed by Director Shizuo Akira, an eminent immunologist, IFReC convenes approximately 30 of the world’s top-class principal investigators from Japan and overseas in the fields of immunology, live imaging and bioinformatics to conduct innovative immunological research. In March 2011, a new research building was completed on Osaka University’s Suita Campus providing superior research facilities and an international environment in which to focus on research. Immunology is definitely important in human health and social welfare. The researchers of IFReC have published over one thousand papers during 2007 to 2015. Almost 10% of them were published in high-impact journals such as Science, Cell, Nature, and their journal families. The production of Top 1% and Top 10% articles are much higher than average. The amount of competitive research funds obtained by IFReC researchers well exceeds the WPI program subsidy.
    [Show full text]
  • Preliminary Program
    Preliminary Program Monday, June 22 7:00 AM – 5:00 PM Registration Desk Open (4th Floor) FOCISed Courses (separate registration required) 7:30 AM – 5:00 PM Systems Immunology Course 8:00 AM – 5:30 PM Basic Immunology in Medicine: Update 2020 Course Tuesday, June 23 7:00 AM – 5:00 PM Registration Desk Open (4th Floor) FOCISed Courses (separate registration required) 8:00 AM – 12:00 PM Big Data ImmPort Workshop Sponsored by ImmPort. Supported by National Institute of Allergy and Infectious Diseases (NIAID) 8:00 AM – 4:30 PM Cancer Immunity & Immunotherapy Course Organized in collaboration with Society of Immunotherapy of Cancer (SITC) Member Society Symposia (included in FOCIS 2020 registration) 8:00 AM – 11:30 AM TBD FCE Fusion: Careers. Collaboration. Connection. (Invitation Only) 11:30 AM – 1:30 PM Member Society Symposia 12:30 PM – 4:00 PM TBD Updated December 18, 2019 Preliminary Program Opening Keynote Address 4:30 PM – 5:15 PM Opening Keynote Address Tasuku Honjo, MD, PhD, Kyoto University Opening Exhibit and Poster Reception (authors present) 5:15 PM – 6:45 PM Opening Reception: Exhibits & Poster Presentations Network with attendees while visiting exhibits and posters with authors present. Complimentary light hors d’oeuvres and wine served. FOCIS Member Reception (FOCIS members only) 7:00 PM – 8:00 PM Join us for hors d’oeuvres, drinks and fun! Let FOCIS show you how much we value you! Not a member? Join now at the registration desk. Wednesday, June 24 7:00 AM – 5:00 PM Registration Desk Open (4th Floor) Plenary Sessions 8:00 AM – 9:30 AM FOCIS 20th Anniversary 8:00 AM Title TBD Maria-Grazia Roncarolo, MD, Stanford University 8:30 AM Title TBD C.
    [Show full text]
  • Loss of Transcription Factor IRF-1 Affects Tumor Susceptibility in Mice Carrying the Ha- Ras Transgene Or Nullizygosity for P53
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press RESEARCH COMMUNICATION Accumulating evidence has also suggested that IRF-1 Loss of transcription factor controls tumor susceptibility. Transformed phenotypes IRF-1 affects tumor of c-myc-orfosB-expressing cells, for example, can be susceptibility in mice carrying suppressed by ectopic expression of IRF-1 (Tanaka et al. 1994b). Furthermore, unlike primary mouse embryonic the Ha-ras transgene fibroblasts (MEFs) from wild-type mice, MEFs from mu- or nullizygosity for p53 tant mice homozygous for IRF-1 deficiency undergo transformation upon expression of an activated form of Hiroaki Nozawa,1,2 Eri Oda,1 Kazuki Nakao,3 c-Ha-ras (Tanaka et al. 1994a). In addition, IRF-1 is es- Masahiko Ishihara,1 Seiji Ueda,1 Taeko Yokochi,1 sential to DNA damage-induced apoptosis in proliferat- Kouetsu Ogasawara,1 Yoko Nakatsuru,4 ing T lymphocytes and MEFs expressing an activated Seiichiro Shimizu,4 Yoshikazu Ohira,4 form of c-Ha-ras (Tanaka et al. 1994a; Tamura et al. 1995). Interestingly, IRF-1 also regulates DNA damage- Kyoji Hioki,5 Shinichi Aizawa,6 induced cell cycle arrest in collaboration with the tumor Takatoshi Ishikawa,4 Motoya Katsuki,3 2 1 suppressor p53 through transcriptional activation of the Tetsuichiro Muto, Tadatsugu Taniguchi, p21WAF1/CIP1 gene (Tanaka et al. 1996). 1,7 and Nobuyuki Tanaka The human IRF-1 gene has been mapped to 5q31.1 1Department of Immunology, 2Department of Surgical (Willman et al. 1993). Genetic as well as epigenetic al- Oncology, and 4Department of Pathology, Graduate School terations in IRF-1 gene expression have been reported in of Medicine and Faculty of Medicine, University of Tokyo, human cancers.
    [Show full text]